RespireRx Pharmaceuticals Inc (RSPI)

[atheroprevent]

Asuhowe, why back off so early, at the brink of greater reward. Financing and dilution can be done positively with regard to SP, with the right partner, once human RD benefit is demonstrated with analgesia preservation. R+R will not be involved. I know it has been disastrous so far, for most of us, but......

My positive expectations are for the first three.

1) Cor drifts up to 1 in June cautiously anticipating positive RD outcome,

2) then doubles on a positive signal from the first RD study.

3) BP interest is tweaked and deal is inked with data from the second RD trial late in July. Stock doubles again as 30 million shares are offered to the partnering pharma, allowing Cor to finance the future. (Step 3 could occur overnight with simultaneous release of the second RD data and partnering anouncement)

4) So the best may be yet to follow, but that would be another level of risk, entailing tangling with the FDA again, but with BP support.